Very excited! ARX marker will cover what PNV has presence in impaired healing likediabetic foot ulcers and venous leg ulcers when Symphony is granted by FDA!
Quoted below:
Aroa also has a pipeline of additional products under development based on the Endoform® technology. This includes Symphony, a skin substitute for closing wounds in patients with severely impaired healing (e.g. diabetic foot ulcers and venous leg ulcers) and a single-use negative pressure wound therapy (sNPWT) product with an Endoform® interface for complex wounds and dead space management.
Very excited! ARX marker will cover what PNV has presence in...
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
-0.015(2.80%) |
Mkt cap ! $178.9M | |||
| Open | High | Low | Value | Volume |
| 54.5¢ | 54.5¢ | 51.0¢ | $577.9K | 1.112M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 428 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.5¢ | 12000 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| ARX (ASX) Chart |